BCL2 and acute myeloid leukemia: Since the publication of the phase III Viale-A trial in 2020 [1], the combination of the BCL-2 selective inhibitor venetoclax and azacytidine (VenAza) has become the gold standard frontline treatment for patients diagnosed with acute myeloid leukemia (AML) ineligible for intensive chemotherapy, also known as unfit patients.